https://u18666ainhibitor.com/i....mproved-probability-
The POLE ultramutated type, the mismatch repair defect type, the TP53 mutant type, and the non-specific molecular characteristic type accounted for 114% (29 out of 254), 315% (80 out of 254), 224% (57 out of 254), and 346% (88 out of 254) of the cases, respectively. The use of Sanger sequencing to evaluate POLE and TP53 led to prevalence figures of 91% (23/254), 315% (80/254), 129% (33/254), and 46
Like
Comment
Share
